Chronic lymphocytic leukemia-associated autoimmune hemolytic anemia

References

• Hamblin T J, Oscier D G, Young B J. Autoimmunity in chronic lymphocytic leukemia. J Clin Pathol 1986; 39: 713–716
   PubMed Web of Science ®Google Scholar
• Duhrsen U, Augener W, Zwingers T, Brittinger G. Spectrum and frequency of autoimmune derangements in lymphoproliferative disorders: analysis of 637 cases and comparison with myeloproliferative diseases. Br J Haematol 1987; 67: 235–239
   PubMed Web of Science ®Google Scholar
• Diehl L F, Ketchum L H. Autoimmune disease and chronic lymphocytic leukemia: autoimmune hemolytic anemia, pure red cell aplasia, and autoimmune thrombocytopenia. Semin Oncol 1998; 25: 80–97
   PubMed Web of Science ®Google Scholar
• Hamblin T. Autoimmune disease and its management in chronic lymphocytic leukemia. Chronic Lymphoid Leukemias, B D Cheson. Marcel Dekker, New York 2000; 435–458
   Google Scholar
• Hamblin T J. Autoimmune complications of chronic lymphocytic leukemia. Semin Oncol 2006; 33: 230–239
   PubMed Web of Science ®Google Scholar
• Sallah S, Wan J Y, Hanrahan L R. Future development of lymphoproliferative disorders in patients with autoimmune hemolytic anemia. Clin Cancer Res 2001; 7: 791–794
   PubMed Web of Science ®Google Scholar
• Ruzickova S, Pruss A, Odendahl M, Wolbart K, Burmester G-R, Scholze J, et al. Chronic lymphocytic leukemia preceded by cold agglutinin disease: intraclonal immunoglobulin light-chain diversity in VH4-34 expressing single leukemic B cells. Blood 2002; 100: 3419–3422
   PubMed Web of Science ®Google Scholar
• Landgren O, Engels E A, Caporaso N E, Gridley G, Mellemkjaer L, Hemminki K, et al. Patterns of autoimmunity and subsequent chronic lymphocytic leukaemia in Nordic countries. Blood 2006; 108: 292–296
   PubMed Web of Science ®Google Scholar
• De Rossi G, Granati L, Girelli G, Gandolfo G, Arista M C, Martelli M, et al. Incidence and significance of autoantibodies against erythrocytes and platelets in chronic lymphocytic leukemia (CLL). Nouv Rev Fr Hematol 1988; 30: 403–406
   PubMedGoogle Scholar
• Michiels J J, Budde U, van der Planken M, van Vliet H H, Schroyens W, Berneman Z. Acquired von Willebran syndromes: clinical features, aetiology, pathophysiology, classification and management. Best Pract Res Clin Haematol 2001; 401–436
   PubMed Web of Science ®Google Scholar
• Mateo J, Martino R, Borrell M, Gari M, Casas F, Fontcuberta J. Acquired factor VIII inhibitor preceding chronic lymphocytic leukemia. Ann Hematol 1993; 67: 309–311
   PubMed Web of Science ®Google Scholar
• Lipscombe T K, Orton D I, Bird A G, Wilkinson J D. Acquired C1-esterase inhibitor deficiency: three case reports and commentary on the syndrome. Australas J Dermatol 1996; 37: 145–148
   PubMedGoogle Scholar
• Hansen M M. Chronic lymphocytic leukemia: clinical studies based on 189 cases followed for a long time. Scand J Haematol 1973; 18: 3–286
   Google Scholar
• Orfao A, Gonzàles M, San Miguel J F, et al. Leucemia linfàtica cronica B: anemias hemoliticas autoimmunes versus anemias debidas a un fallo medular. Sangre 1988; 33: 296–300
   PubMedGoogle Scholar
• Mauro F R, Foà R, Cerretti R, Giannarelli D, Coluzzi S, Girelli G. Autoimmune hemolytic anemia in chronic lymphocytic leukemia: clinical, therapeutic, and prognostic features. Blood 2000; 95: 2786–2792
   PubMed Web of Science ®Google Scholar
• Kyasa M J, Parrish R S, Schichman S A, Zent C S. Autoimmune cytopenia does not predict poor prognosis in chronic lymphocytic leukemia/small lymphocytic lymphoma. Am J Hematol 2003; 74: 1–8
   PubMed Web of Science ®Google Scholar
• Shanafelt T D, Geyer S M, Kay N E. Prognosis at diagnosis: integrating molecular biologic insight into clinical practice for patients with CLL. Blood 2004; 103: 1202–1210
   PubMed Web of Science ®Google Scholar
• Fagiolo E, Toriani-Terenzi C. Mechanisms of immunological tolerance loss versus erythrocyte self-antigens and autoimmune hemolytic anemia. Autoimmunity 2003; 36: 199–204
   PubMed Web of Science ®Google Scholar
• Semple J W, Freedman J. Autoimmune pathogenesis and autoimmune hemolytic anemia. Semin Hematol 2005; 42: 122–130
   PubMed Web of Science ®Google Scholar
• Bartik M M, Welker D, Kay N E. Impairments in immune cell function in B cell chronic lymphocytic leukemia. Semin Oncol 1998; 25: 27–33
   PubMed Web of Science ®Google Scholar
• Podstawka U, Kopec-Szlezak J, Palynyczko G, Mendek-Czajkowska E, Konopka L. Non-neoplastic lymphocyte subsets in patients with B-cell chronic lymphocytic leukemia (B-CLL). Med Sci Monit 1999; 5: 239–245
   Google Scholar
• Scrivener S, Kaminski E R, Demaine A, Prentice A G. Analysis of the expression of critical activation/interaction markers on peripheral blood T cells in B-cell chronic lymphocytic leukaemia: evidence of immune dysregulation. Br J Haematol 2001; 112: 959–964
   PubMed Web of Science ®Google Scholar
• Scrivener S, Goddard R V, Kaminski E R, Prentice A G. Abnormal T-cell function in B-cell chronic lymphocytic leukemia. Leuk Lymphoma 2003; 44: 383–389
   PubMed Web of Science ®Google Scholar
• Messmer B T, Albesiano E, Efremov D G, Ghiotto F, Allen S L, Kolitz J, et al. Multiple distinct sets of stereotyped antigen receptors indicate a role for antigen in promoting chronic lymphocytic leukemia. J Exp Med 2004; 200: 519–525
   PubMed Web of Science ®Google Scholar
• Keating M J, O'Brien S, Lerner S, Koller C, Beran M, Robertson L E, et al. Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy. Blood 1998; 92: 1165–1171
   PubMed Web of Science ®Google Scholar
• Hamblin T J, Orchard J A, Myint H, Oscier D G. Fludarabine and hemolytic anemia in chronic lymphocytic leukemia (letter). J Clin Oncol 1998; 16: 3209–3210
   PubMed Web of Science ®Google Scholar
• Sthoeger Z M, Sthoeger D, Shtairid M, Sigler E, Geltner D, Berrebl A. Mechanism of autoimmune hemolytic anemia in chronic lymphocytic leukemia. Am J Hematol 1993; 43: 259–264
   PubMed Web of Science ®Google Scholar
• Kipps T, Carson D A. Autoantibodies in chronic lymphocytic leukemia and related systemic autoimmune diseases. Blood 1993; 81: 2475–2487
   PubMed Web of Science ®Google Scholar
• Caligaris-Cappio F, Hamblin T J. B-cell chronic lymphocytic leukemia: a bird of a different feather. J Clin Oncol 1999; 17: 399–408
   PubMed Web of Science ®Google Scholar
• Barcellini W, Montesano R, Clerici G, Zaninoni A, Imperiali F G, Calori R, et al. In vitro production of anti-RBC antibodies and cytokines in chronic lymphocytic leukemia. Amer J Hematol 2002; 71: 177–183
   PubMed Web of Science ®Google Scholar
• Mosier D E, Gulizia R J, Baird S M, Wilson D B. Transfer of a functional human immune system to mice with severe combined immunodeficiency. Nature 1988; 335: 256–259
   PubMed Web of Science ®Google Scholar
• Mosier D E, Baird S M, Kirven M B, Gulizia R J, Wilson D B, Kubayashi R, et al. EBV-associated B-cell lymphomas following transfer of human peripheral blood lymphocytes to mice with severe combined immune deficiency. Curr Top Microbiol Immunol 1990; 166: 317–323
   PubMed Web of Science ®Google Scholar
• Rowe M, Young L S, Crocker J, Stokes H, Henderson S, Rickinson A B. Epstein-Barr virus (EBV)-associated lymphoproliferative disease in the SCID mouse model: implications for the pathogenesis of EBV-positive lymphomas in man. J Exp Med 1991; 173: 147–153
   PubMed Web of Science ®Google Scholar
• Hall A W, Vickers M A, McLeod E, Barker R N. Rh autoantigen presentation to helper T cells in chronic lymphocytic leukemia by malignant B cells. Blood 2005; 105: 2007–2015
   PubMed Web of Science ®Google Scholar
• Porakishvili N, Mageed R, Jamin C, Pers J-O, Kulikova N, Renaudineau Y, et al. Recent understanding of B-cell function in autoimmunity. Scand J Immunol 2001; 54: 30–38
   PubMed Web of Science ®Google Scholar
• Bastion Y, Coiffier B, Dumonet C, Espinouse D, Byron P A. Severe autoimmune hemolytic anemia in two patients treated with fludarabine for chronic lymphocytic leukemia. Ann Oncol 1992; 3: 171–172
   PubMed Web of Science ®Google Scholar
• Tosti S, Caruso R, D'Adamo F, Picardi A, Ali Ege M, Girelli G, et al. Severe autoimmune hemolytic anemia in a patient with chronic lymphocytic leukemia responsive to fludarabine-based treatment. Ann Hematol 1992; 65: 238–239
   PubMed Web of Science ®Google Scholar
• Di Raimondo F, Giustolisi R, Cacciola E, O'Brien S, Kantarjian H, Robertson L B, et al. Autoimmune hemolytic anemia in chronic lymphocytic leukemia patients treated with fludarabine. Leuk Lymphoma 1993; 11: 63–68
   PubMed Web of Science ®Google Scholar
• Byrd J C, Hertler A A, Weiss R B, Freiman J, Kweeder S L, Diehl L F. Fatal recurrence of autoimmune hemolytic anemia following pentostatin therapy in a patient with a history of fludarabine-associated hemolytic anemia. Ann Oncol 1995; 6: 300–301
   PubMed Web of Science ®Google Scholar
• Lopez L, del Villar V, Pascual T. Fludarabine and fatal hemolytic anemia. Sangre 1995; 40: 335–336
   PubMedGoogle Scholar
• Myint H, Copplestone J A, Orchard J, Craig V, Curtis D, Prentice A G, et al. Fludarabine-related autoimmune haemolytic anaemia in patients with chronic lymphocytic leukaemia. Br J Haematol 1995; 91: 341–344
   PubMed Web of Science ®Google Scholar
• Crozat-Grosleron S, Reynaud D, Yeche S, Rossi J F, Dubois A. Fludarabine and severe autoimmune hemolytic anemia: a new case. Rev Med Interne 1996; 17: 701–702
   PubMed Web of Science ®Google Scholar
• Maclean R, Meiklejohn D, Soutar R. Fludarabine-related autoimmune hemolytic anaemia in patients with chronic lymphocytic leukaemia. Br J Haematol 1996; 92: 768–769
   PubMed Web of Science ®Google Scholar
• Tertian G, Carton J, Bayle C, Rudent A, Lambert T, Tchernia G. Fatal intravascular autoimmune hemolytic anemia after fludarabine treatment for chronic lymphocytic leukemia. Hematol Cell Ther 1996; 38: 359–360
   PubMedGoogle Scholar
• Tsiara S, Christou L, Kostantinidou P, Panteli A, Briasoulis E, Bourantas K L. Severe autoimmune hemolytic anemia following fludarabine therapy in a patient with chronic lymphocytic leukemia. Am J Hematol 1997; 54: 342
   PubMed Web of Science ®Google Scholar
• Longo G, Gandini G, Ferrara L, Torelli U, Emilia G. Fludarabine and autoimmune hemolytic anemia in chronic lymphocytic leukemia. Eur J Haematol 1997; 59: 124–125
   PubMed Web of Science ®Google Scholar
• Shvidel L, Shtarlid M, Klepfish A, Sigler E, Berrei A. Evans syndrome complicating fludarabine treatment for advanced B-CLL. Br J Haematol 1997; 99: 706
   PubMed Web of Science ®Google Scholar
• Vick D J, Byrd J C, Beal C L, Chaffin D J. Mixed-type autoimmune hemolytic anemia following fludarabine treatment in a patient with chronic lymphocytic leukemia/small cell lymphoma. Vox sang 1998; 74: 122–126
   PubMed Web of Science ®Google Scholar
• Weiss R B, Freiman J, Kweder S L, Diehl L F, Byrd J. Hemolytic anemia after fludarabine therapy for chronic lymphocytic leukemia. J Clin Oncol 1998; 16: 1885–1889
   PubMed Web of Science ®Google Scholar
• Gonzales H, Leblond V, Azar N, Sutton L, Gabarre J, Binet J L, et al. Severe autoimmune hemolytic anemia in eight patients treated with fludarabine. Hematol Cell Ther 1998; 40: 113–118
   PubMedGoogle Scholar
• Taha H M, Narasihman P, Venkatesh L, Cawley M, Kaplan B. Fludarabine-related hemolytic anemia in chronic lymphocytic leukemia and lymphoproliferative disorders. Am J Hematol 1998; 59: 316
   PubMed Web of Science ®Google Scholar
• Sen K, Kalaycio M. Evan's syndrome precipitated by fludarabine therapy in a case of CLL. Am J Hematol 1999; 61: 219
   PubMed Web of Science ®Google Scholar
• Leporrier M, Chevret S, Cazin B, Boudjerra N, Feugier P, Desanblens B, et al. Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients. Blood 2001; 98: 2319–2325
   PubMed Web of Science ®Google Scholar
• Catovsky D, Richards S. Incidence of hemolytic anemia after chemotherapy in the CLL4 Trial. A possible role for fludarabine plus cyclophosphamide (Abstract). Blood 2004; 104(Suppl 1)480
   Google Scholar
• Steurer M, Pall G, Richards S, Schwarzer G, Bohlius J, Greil R. Purine antagonists for chronic lymphocytic leukemia: results of a comprehensive meta-analysis (Abstract). Ann Oncol 2005; 16(Suppl 5)569
   Google Scholar
• Eichhorst B F, Busch R, Hopfinger G, Pasold R, Henseld M, Steinbrecher C, et al. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood 2006; 107: 885–891
   PubMed Web of Science ®Google Scholar
• Hale G, Xia M Q, Tighe H P, Dyer M JS, Waldmann H. The Campath-1 antigen (CD52). Tissue Antigens 1990; 35: 118–127
   PubMed Web of Science ®Google Scholar
• Otton S H, Turner D L, Frewin R, Davies S V, Johnson S A. Autoimmune thrombocytopenia after treatment with Campath-1H in a patient with chronic lymphocytic leukaemia. Br J Haematol 1999; 106: 252–262
   PubMed Web of Science ®Google Scholar
• D'Arena G, De Filippi R, Pinto A. DAT-negative hemolytic anemia in a chronic lymphocytic leukemia patient treated with alemtuzumab. Leuk Lymphoma 2007; 48: 625–627
   PubMed Web of Science ®Google Scholar
• Chrousos G P, Wilder R L, Cupps T R, Balow J E. Glucocorticoid therapy for immune-mediated diseases: basic and clinical correlates. Ann Intern Med 1993; 119: 1198–1208
   PubMed Web of Science ®Google Scholar
• Petz L D, Garatty G. Management of autoimmune haemolytic anemias. Immune Hemolytic Anemias, L D Petz, G Garatty. Chruchill Livingstone, Philadelphia 2004; 401–458
   Google Scholar
• Juliusson G. Complications in the treatment of CLL with purine analogues. Hematol Cell Ther 1997; 39(Suppl 1)41–44
   PubMedGoogle Scholar
• Coon W W. Splenectomy in the treatment of haemolytic anemia. Arch Surg 1985; 120: 625–628
   PubMed Web of Science ®Google Scholar
• Coad J E, Matutes E, Catovsky D. Splenectomy in lymphoproliferative disorders: a report on 70 cases and review of the literature. Leuk Lymphoma 1993; 10: 245–264
   PubMed Web of Science ®Google Scholar
• Cusack J C, Seymour J F, Lerner S A, Pollock R E, Keating M J. Role of splenectomy in chronic lymphocytic leukaemia. J Am Coll Surg 1997; 185: 237–243
   PubMed Web of Science ®Google Scholar
• Seymour J F, Cusack J D, Lerner S A, Pollock R E, Keating M J. Case/control study of the role of splenectomy in chronic lymphocytic leukemia. J Clin Oncol 1997; 15: 52–60
   PubMed Web of Science ®Google Scholar
• Neal T F, Jr, Tefferi A, Witzig T E, Su J, Phyliky R L, Nagorney D M. Splenectomy in advanced chronic lymphocytic leukaemia: a single institution experience with 50 patients. Am J Med 1992; 93: 435–440
   PubMed Web of Science ®Google Scholar
• Akpek G, McAneny D, Weintraub L. Comparative response to splenectomy in Coombs-positive autoimmune haemolytic anemia with or without associated disease. Am J Hematol 1999; 61: 98–102
   PubMed Web of Science ®Google Scholar
• Besa E C. Use of intravenous immunoglobulin in chronic lymphocytic leukemia. Am J Med 1984; 76: 209–218
   PubMed Web of Science ®Google Scholar
• Besa E C. Rapid transient reversal of anemia and long-term effects of maintenance intravenous immunoglobulin for autoimmune hemolytic anemia in patients with lymphoproliferative disorders. Am J Med 1988; 84: 691–698
   PubMed Web of Science ®Google Scholar
• Herhko C, Sonnenblick M, Ashkenazi J. Control of steroid-resistant autoimmune haemolytic anemia by cyclosporin. Br J Haematol 1900; 76: 436–437
   Web of Science ®Google Scholar
• Ruess-Borst M A, Waller H D, Muller C A. Successful treatment of steroid-resistant hemolysis in chronic lymphocytic lekaemia with cyclosporin A. Am J Hematol 1994; 46: 375–376
   PubMed Web of Science ®Google Scholar
• Emilia G, Messora C, Bensi L. The use of cyclosporin-A in the treatment of B-chronic lymphocytic leukemia. Leukemia 1995; 9: 357–359
   PubMed Web of Science ®Google Scholar
• Sigler E, Shtalrid M, Goland S, Sthoeger Z M, Berrebi A. Intractable acute autoimmune haemolytic anemia in B-cell chronic lymphocytic leukaemia successfully treated with vincristine-loaded platelet infusion. Am J Hematol 1995; 50: 313–315
   PubMed Web of Science ®Google Scholar
• Lundin J, Osterborg A. Advances in the use of monoclonal antibodies in the therapy of chronic lymphocytic leukemia. Semin Hematol 2004; 41: 234–245
   PubMed Web of Science ®Google Scholar
• Robak T. Monoclonal antibodies in the treatment of autoimmune cytopenias. Eur J Haematol 2004; 72: 79–88
   PubMed Web of Science ®Google Scholar
• Reiff A. A review of Campath in autoimmune disease: biologic therapy in the gray zone between immunosuppression and immunoablation. Hematology 2005; 10: 79–93
   PubMed Web of Science ®Google Scholar
• Silverman G J, Weisman S. Rituximab therapy and autoimmune disorders prospects for anti-B cell therapy. Arthritis Rheum 2003; 48: 1484–1492
   PubMed Web of Science ®Google Scholar
• Reff M E, Carner K, Chambers K S, Chinn P C, Leonard J E, Raab R, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994; 83: 435–445
   PubMed Web of Science ®Google Scholar
• Killick S B, Marsh J CW, Hale G, Waldmann H, Kelly S J, Gordon-Smith E C. Sustained remission of severe resistant autoimmune neutropenia with Campath-1H. Br J Haematol 1997; 97: 306–308
   PubMed Web of Science ®Google Scholar
• Willis F, Marsh J CW, Bevan D H, Killick S B, Lucas G, Griffiths R, et al. The effect of treatment with Campath-1H in patients with autoimmune cytopenia. Br J Haematol 2001; 114: 891–898
   PubMed Web of Science ®Google Scholar
• Marsh J CW, Gordon-Smith E C. Campath-1H in the treatment of autoimmune cytopenias. Cytotherapy 2001; 3: 189–195
   PubMed Web of Science ®Google Scholar
• Seipelt G, Bohme A, Koschmieder S, Hoelzer D. Effective treatment with rituximab in a patient with refractory prolymphocytoid transformed B-chronic lymphocytic leukemia and Evans syndrome. Ann Hematol 2001; 80: 170–173
   PubMed Web of Science ®Google Scholar
• Gupta N, Kavuru S, Patel D, Janson D, Driscoll N, Ahmed S, et al. Rituximab-based chemotherapy for steroid-refractory autoimmune hemolytic anemia of chronic lymphocytic leukemia. Leukemia 2002; 16: 2092–2095
   PubMed Web of Science ®Google Scholar
• Trapè G, Fianchi L, Lai M, Laurenti L, Piscitelli R, Leone G, et al. Rituximab chimeric anti-CD20 monoclonal antibody treatment for refractory hemolytic anemia in patients with lymphoproliferative disorders. Haematologica 2003; 88: 223–225
   PubMed Web of Science ®Google Scholar
• Zaja F, Vianelli N, Sperotto A, Patriarca F, Tani M, Marin L, et al. Anti-CD20 therapy for chronic lymphocytic leukemia-associated autoimmune diseases. Leuk Lymphoma 2003; 44: 1951–1955
   PubMed Web of Science ®Google Scholar
• D'Arena G, Laurenti L, Capalbo S, D'Arco A M, De Filippi R, Marcacci G, et al. Rituximab therapy for chronic lymphocytic leukemia-associated autoimmune hemolytic anemia. Am J Hematol 2006; 81: 598–602
   PubMed Web of Science ®Google Scholar
• Iannitto E, Ammatuna E, Marino C, Cirrincione S, Greco G, Mariani G. Sustained response of refractory chronic lymphocytic leukemia in progression complicated by acute hemolitic anemia to anti-CD20 monoclonal antibody. Blood 2002; 99: 1096–1097
   PubMed Web of Science ®Google Scholar
• Chemnitz J, Draube A, Diehl V, Wolf J. Successuful treatment of steroid and cyclophosphamide-resistant hemolysis in chronic lymphocytic leukemia with rituximab. Am J Hematol 2002; 69: 232–233
   PubMed Web of Science ®Google Scholar
• Shivdel L, Shtalride M, Berrei A. Intractable autoimmune hemolytic anemia in B cell chronic lymphocytic leukemia resolved by rituximab. Leuk Lymphoma 2004; 45: 1493–1494
   PubMed Web of Science ®Google Scholar
• Paydas S. Fludarabine-induced hemolytic anemia: successful treatment by rituximab. Hematol J 2004; 5: 81–83
   PubMedGoogle Scholar
• Narat S, Gandla J, Hoffbrand A V, Hughes R G, Mehta A B. Rituximab in the treatment of refractory autoimmune cytopenias in adults. Haematologica 2005; 90: 1273–1274
   PubMed Web of Science ®Google Scholar
• Nishida H, Murase T, Ueno H, Park J W, Yano T, Ikeda Y. Fludarabine-associated autoimmune hemolytic anemia occurring in B-cell chronic lymphocytic leukemia. Leuk Res 2007; 31: 268–269
   Web of Science ®Google Scholar
• Pamuk G E, Turgut B, Demir M, Tezcan F, Vural O. The successful treatment of refractory autoimmune hemolytic anemia with rituximab in a patient with chronic lymphocytic leukemia. Am J Hematol 2006; 81: 631–633
   PubMed Web of Science ®Google Scholar
• Swords R, Nolan A, Fay M, Quinn J, O'Donnell R, Murphy P T. Treatment of refractory fludarabine induced autoimmune haemolysis with the anti-CD20 monoclonal antibody rituximab. Clin Lab haematol 2006; 28: 57–59
   PubMedGoogle Scholar
• Jourdan E, Topart D, Richard B, Jourdan J, Sotto A. Severe autoimmune hemolytic anemia following rituximab therapy in a patient with a lymphoproliferative disorder. Leuk Lymphoma 2003; 44: 889–890
   PubMed Web of Science ®Google Scholar
• Rodon P, Breton P, Courouble G. Treatment of pure red cell aplasia and autoimmune haemolytic anaemia in chronic lymphocytic leukaemia with Campath-1H. Br J Haematol 2003; 70: 319–321
   Web of Science ®Google Scholar
• Lundin J, Karlsson C, Celsing F. Alemtuzumab therapy for severe autoimmune hemolysis in a patient with B-cell chronic lymphocytic leukemia. Med Oncol 2006; 1: 137–139
   Web of Science ®Google Scholar
• Karlsson C, Hansson L, Celsing F, Lundin J. Treatment of severe refractory autoimmune hemolytic anemia in B-cell chronic lymphocytic leukemia with alemtuzumab (humanized CD52 monoclonal antibody). Leukemia 2007; 21: 511–514
   PubMed Web of Science ®Google Scholar